For Research Use Only · Not For Human or Veterinary Use · Not FDA-Approved

— Research monograph

KLOW Blend (BPC-157 · GHK-Cu · TB-500 · KPV)

KLOWfour-peptide blend

A four-peptide repair blend adding the KPV tripeptide to the GLOW base.

Updated

Class
Merit co-formulation: BPC-157 + GHK-Cu + TB-500 + KPV
Half-life (research)
Component-dependent (see the individual component records).
Origin
KLOW is a Merit-specific four-component co-formulation. It extends the GLOW blend with KPV, the C-terminal tripeptide (lysine-proline-valine) of alpha-melanocyte-stimulating hormone (α-MSH).
Solubility
Water-soluble. Physicochemical context only. Merit Sciences publishes no reconstitution or preparation procedures.

What is KLOW Blend (BPC-157 · GHK-Cu · TB-500 · KPV)?

KLOW combines four peptides recurrent in repair and immune-signaling research: BPC-157, GHK-Cu, TB-500, and KPV. KPV is the C-terminal fragment of α-MSH and is studied for anti-inflammatory signaling that appears, in some models, to act independently of the melanocortin-1 receptor.

As a co-formulation, KLOW has no separate published record; the literature belongs to each component. Merit supplies it as a single research preparation for laboratory use only.

How does KLOW Blend (BPC-157 · GHK-Cu · TB-500 · KPV) work?

Component-level: BPC-157 (cytoprotection / angiogenesis), GHK-Cu (matrix remodeling), TB-500 (actin / cell migration), and KPV (NF-κB-pathway modulation in inflammation models). No combined mechanism is established for the blend.

Research applications

  • Tissue-repair and remodeling research (component-based)
  • Inflammation-pathway models (KPV)
  • Extracellular-matrix studies
  • Comparative peptide co-formulation research

KLOW Blend (BPC-157 · GHK-Cu · TB-500 · KPV) at Merit

Form & storage

KLOW Blend (BPC-157 · GHK-Cu · TB-500 · KPV) ships as a sealed, lyophilized (freeze-dried) powder. Water-soluble. Physicochemical context only. Merit Sciences publishes no reconstitution or preparation procedures. Store sealed, light-protected, and follow your institution’s handling procedures for research materials.

Frequently asked questions

What is KLOW Blend (BPC-157 · GHK-Cu · TB-500 · KPV)?

KLOW combines four peptides recurrent in repair and immune-signaling research: BPC-157, GHK-Cu, TB-500, and KPV. KPV is the C-terminal fragment of α-MSH and is studied for anti-inflammatory signaling that appears, in some models, to act independently of the melanocortin-1 receptor. Merit supplies it as a lyophilized research compound for research use only, not for human or veterinary use.

How does KLOW Blend (BPC-157 · GHK-Cu · TB-500 · KPV) work?

Component-level: BPC-157 (cytoprotection / angiogenesis), GHK-Cu (matrix remodeling), TB-500 (actin / cell migration), and KPV (NF-κB-pathway modulation in inflammation models). No combined mechanism is established for the blend. Mechanistic descriptions summarize published preclinical findings and are not clinical claims.

What is the half-life of KLOW Blend (BPC-157 · GHK-Cu · TB-500 · KPV)?

Component-dependent (see the individual component records). Values reflect preclinical or research-context reports, not clinical pharmacokinetics.

Is Merit KLOW Blend (BPC-157 · GHK-Cu · TB-500 · KPV) for human use?

No. It is sold strictly for research use only: not for human or veterinary use, and not for diagnostic or therapeutic use.

Is KLOW Blend (BPC-157 · GHK-Cu · TB-500 · KPV) FDA-approved?

None of its components (BPC-157, GHK-Cu, TB-500, KPV) is approved by the FDA for any use, and no FDA-approved product combines them. Supplied for research use only. Two components are named on the WADA 2026 Prohibited List: BPC-157 under S0 and TB-500 under S2.

How is each batch of KLOW Blend (BPC-157 · GHK-Cu · TB-500 · KPV) tested?

Every Merit batch is tested by an independent laboratory for identity and HPLC purity before it is listed, and Merit identifies batches by date rather than by lot number. Current certificates: KLOW (BPC-157, GHK-Cu, TB-500, KPV) 80 mg, July 2026 batch, 99.79% purity (meritsciences.com/coa/COA-2026-5HUDMG).

Regulatory status checked October 22, 2026 against: committee vote report (Healio), FDA 503A categories list, FDA Category 2 list, WADA Prohibited List.

References

  1. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, et al.. Gastroenterology, 2008 · doi:10.1053/j.gastro.2007.10.026
  2. Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. Sikiric P, Seiwerth S, Rucman R, et al.. Current Pharmaceutical Design, 2011 · doi:10.2174/138161211796196954

For research use only. Not for human or veterinary use. Reference information summarized from published literature, not medical advice.